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Abstract: Ganciclovir (GCV) is a nucleoside analogue with antiviral activity against
herpes viral infections, and the most widely used antiviral to treat cytomegalovirus
infections. However, the low bioavailability and short half-life of GCV necessitate the
development of a carrier for sustained delivery. In this study, guanosine-based GCV was
used as the initiator directly in ring-opening polymerization of ε-caprolactone (ε-CL) to
form hydrophobic GCV-poly(caprolactone) (GCV-PCL) which was then grafted with
hydrophilic chitosan to form amphiphilic copolymers for the preparation of stable micellar
nanoparticles. Successful synthesis of GCV-PCL and GCV-PCL-chitosan were verified by
1
H-NMR analysis. Self-assembled micellar nanoparticles were characterized by dynamic
light scattering and zetasizer with an average size of 117 nm and a positive charge of
24.2 mV. The drug release kinetics of GCV was investigated and cytotoxicity assay
demonstrated that GCV-tagged polymeric micelles were non-toxic. Our results showed that
GCV could be used directly in the initiation of ring-opening polymerization of ε-CL and
non-toxic polymeric micelles for GCV delivery can be formed.
Keywords: chitosan; ganciclovir; poly(caprolactone); ring-opening polymerization

Molecules 2015, 20

2858

1. Introduction
Ganciclovir (GCV), is the most widely used antiviral drug for the treatment of human
cytomegalovirus (CMV) infections [1]. GCV however is only slightly water soluble, and as a result,
has poor oral and ocular bioavailability. Therefore, it needs to be administered intravenously; however,
due to its short biological half-life, frequent dosing is required, which may increase the risk of
systemic toxicity and discomfort to the patient [1–4]. To address the aforementioned problems, several
drug delivery systems have been developed for GCV [5–9]. Incorporation of the drug into
nanoparticles is advantageous because a carrier can protect the drug from enzymatic degradation,
control the drug release rate (leading to enhanced bioavailability), improve the therapeutic effects, and
reduce administration frequency.
In recent years, polymeric micelles have been the focus of much interest as alternative vehicles for
the solubilization of poorly water-soluble molecules rendering clear advantages over current
solubilizing agents in drug delivery [10]. Polymeric micelles are expected to withstand the diluting
effect of blood, stay in a micellar form, and even act as a circulating depot drug delivery system after
intravenous administration. Moreover, there is no inclusion of potentially harmful surfactants and
excipients in the process of encapsulating hydrophobic drug molecules. Due to the fact that micelles
can be specifically synthesized to increase a drug’s solubility and bioavailability, they are a model
system for enhanced drug delivery [11–14].
Poly(ε-caprolactone) (PCL) having been widely used as the core-forming hydrophobic segment of
nanoparticles was selected as the model polymer for this study. PCL is a semi-crystalline linear
resorbable aliphatic polyester. It has been commonly used in drug delivery systems because it is
biodegradable and biocompatible [15–17]. PCL is commonly synthesized by ring-opening polymerization
of ε-caprolactone using an alcohol (R-OH) as an initiator and stannous (II) octoate (Sn(Oct)2) as a
catalyst [18,19]. In addition to using R-OH as the initiator, methoxy-poly(ethylene oxide) and starch
have been employed as macroinitiators to form amphiphilic polymers [20,21]. In this study, prodrug
GCV possessing hydroxyl groups, was used as the initiator to obtain GCV-PCL. Then, hydrophilic
chitosan was grafted on the hydrophobic GCV-PCL to form the amphiphilic block copolymer which
already has the GCV prodrug attached started from the ring-opening polymerization. Chitosan is a
natural polysaccharide derived from deacetylation of chitin. Chitosan’s biocompatible and biodegradable
features have attracted much attention in biomedical and pharmaceutical research [15,21].
The synthesized GCV-tagged amphiphilic copolymer can be self-assembled in aqueous medium to
form polymeric prodrug micelles, which can be used further to treat CMV infections. To this end, the
chemical structure and physical properties of GCV-PCL-chitosan were characterized and polymeric
prodrug micelle formation was investigated. Drug release of GCV from GCV-PCL-chitosan, as well as
the biocompatibility of GCV-tagged polymeric micelles were examined.
2. Results and Discussion
2.1. Synthesis and Characterization of Amphiphilic Prodrug Polymers
GCV-PCL was synthesized through ring-opening polymerization of ε-CL exclusively by GCV
(Scheme 1A) using Sn(Oct)2 as a catalyst. While the mechanism of polymerization with Sn(Oct)2 is
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still unclear, Sn(Oct)2 is not thought to be the actual initiator since polymer molecular weight does not
depend on the monomer-to-Sn(Oct)2 molar ratio [18]. The most widely accepted mechanism for
ring-opening polymerization is a coordination insertion mechanism where the hydroxyl functional
group coordinates to Sn(Oct)2 forming the initiating tin-complex. To show the successful initiation of
ε-CL by GCV, 1H-NMR analysis was conducted. The 1H-NMR spectra of prodrug GCV and GCV-PCL
are shown in Figure 1i,ii, respectively. Chemical shifts at δ = 1.37 (j-CH2), 1.62 (i-CH2), 2.27 (h-CH2)
and 4.04 (k-CH2) ppm correspond with the backbone chain of PCL polymer. Peaks at δ = 3.63 (f-CH2),
5.47 (d-CH2) and 7.76 (b-CH) are assigned to protons in GCV. Evidence of GCV grafting to PCL is
clearly seen by the characteristic resonances observed in the synthesized polymer, confirming the
synthesis of GCV-PCL.
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Scheme 1. Synthetic steps of (A) GCV-PCL, (B) GCV-PCL-COOH, (C) GCV-PCL-NHS,
and (D) GCV-PCL-chitosan.
GCV-PCL was further conjugated with chitosan as shown in Scheme 1B–D. Successful conjugation
of chitosan was confirmed by analytical means. Figure 2 depicts the 1H-NMR analysis of chitosan (iii)
and GCV-PCL-chitosan (iv). As shown in Scheme 1D, conjugation of chitosan to GCV-PCL was
made via amide linkage. The peak at 1.79 (l-NH2) from a singlet to a multiplet in Figure 2iv confirms
conjugation of chitosan to GCV-PCL. Moreover, the peaks from the protons on C3–C6 of chitosan can be
seen from δ = 3.28–3.85, slightly shifted downward from the peaks shown in the original chitosan sample
(Figure 2iii). Moreover, the gel permeation chromatography (GPC) data shown in Figure 3 confirmed
the formation of amphiphilic copolymer GCV-PCL-chitosan. GCV-PCL hydrophobic polymer had an
observed number-average molecular weight (Mn(obsd)) of 11.5 kDa which increased to 17.2 kDa after

Molecules 2015, 20

2860

the addition of chitosan. This corresponds well with the addition of chitosan which had an average
molecular weight of 5 kDa. Furthermore, the polydispersity index (PDI) of both GCV-PCL and
GCV-PCL-chitosan polymer was low at 1.13 and 1.18, respectively which indicate that the polymer chains
are approaching a uniform chain length. The molecular weights of GCV-PCL and GCV-PCL-chitosan
were found via GPC calibrated by polystyrene standards. The data were corrected via Mark-Houwink
correction for Mn(corrected) = 0.56 × Mn(obsd) and the data are shown in Figure 3 [22,23].

Figure 1. 1H-NMR spectra of (i) GCV and (ii) GCV-PCL.
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Figure 2. 1H-NMR spectra of (iii) chitosan and (iv) GCV-PCL-chitosan.
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Figure 3. Characterization of molecular weight profiles of GCV-PCL (- - -) and
GCV-PCL-chitosan (____) by GPC analysis.
2.2. Formation and Characterization of GCV-Tagged Polymeric Micelles
Through the solvent evaporation method, polymeric micelles of GCV-PCL-chitosan were formed.
Here, the hydrophobic core segment was GCV-PCL and chitosan was the cationic and hydrophilic
corona segment. The size of GCV-PCL-chitosan micelles was examined through dynamic light
scattering (DLS) analysis. Figure 4A shows the size of GCV-tagged polymeric micelles. The average
size as reported by DLS was 117 nm with a zeta potential of 24.2 mV (Figure 4B). The positive charge
is attributed to chitosan used as the hydrophilic segment on the micellar carriers. To determine the drug
loading percentage of GCV per mg of prepared micelle solution, the absorbance of GCV-PCL-chitosan
was examined at t = 0 and t = 72 h and compared to a standard calibration curve of GCV ranging from
0.002 to 1.0 mg·mL−1. It was found that GCV comprised 4.8% of the polymeric micelles.
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Figure 4. Physical characterization of GCV-PCL-chitosan micelles, (A) size analysis
reported by DLS and (B) charge reported by zetasizer.
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2.3. In Vitro Release of GCV from Polymeric Micelles

Accumulated release (%)

The in vitro release behavior of GCV at 37 °C in PBS was examined. As can be seen from Figure 5,
the release of GCV took 40 h to reach a maximum release of 77%. Moreover, there was an initial burst
release within the first 2 h, followed by sustained release until 40 h. It is surmised that this burst
release is due to the release of GCV which may already have weakened ester bonds between GCV and
PCL. This is due to the fact that in order to bind chitosan to GCV-PCL-NHS, aqueous solvent is
needed to dissolve chitosan, which can begin the breakage of ester bonds via hydrolysis. When
conjugating GCV-PCL-NHS with methoxypolyethylene glycol amine (MPEG-NH2) in an organic
solvent, the burst release of GCV from prepared GCV-PCL-MPEG micelles was not observed as the
one shown in Figure 5 (data not shown). The release kinetics of GCV from GCV-PCL-chitosan was
modeled using both power-law and Michaelis-Menten-type models. As can be seen from Figure 5,
power-law model was not a good fit for the release of GCV from polymeric micelles. Here, the
exponent, n, was equal to 0.29 in GCV-PCL-chitosan micelles. The exponent, n, of a sphere with
Fickian diffusion as the drug release mechanism is 0.43 according to theoretical calculation [24].
Because our n value is lower than this value, the drug release mechanism of GCV from polymeric
micelles is not solely through diffusion. Instead, the release of GCV from polymeric micelles was
modulated by hydrolysis and diffusion. The ester bond must be first cleaved via hydrolysis and then
GCV can diffuse out of the polymeric micelles. In contrast to the power-law model, the Michaelis-Menten
model fits the release of GCV from polymeric micelles well because GCV release is driven by a
reaction-diffusion mechanism. According to the Michaelis-Menten model, we found that the dissociation
constant (Kd) was equal to 2.79 which is much higher than the release of ACV from ACV-PCL-chitosan
polymeric micelles reported previously [25]. Such extended release of GCV from polymeric micelles
probably is due to the relatively robust binding force between GCV-PCL generated by two hydroxyl
groups existing on GCV, in comparison with only one hydroxyl moiety on ACV.
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Figure 5. In vitro drug release profile of GCV from GCV-PCL-chitosan in PBS at 37 °C
(mean ± SD, n = 3).
2.4. Cytotoxicity Test
For a micelle carrier to be effective for any sort of drug delivery application, biocompatibility is
necessary. To evaluate the toxicity of GCV-PCL-chitosan, HT29 colorectal cancer cells were treated
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with various concentrations of GCV-tagged polymeric micelles ranging from 0–1 mg/mL. As can be
seen in Figure 6A, MTT assay shows that the viability of HT29 cells after 48-h treatment with
GCV-PCL-chitosan had little change when compared with the untreated cells (i.e., the control group).
Moreover, cell images showed that micelle treatment at 1 mg/mL did not alter the growth morphology
of HT29 cells (Figure 6C,E). Figure 6B–E showed that HT29 cells were still able to grow and
proliferate after micelle treatment similar to the control group without any micelle challenge. These
results demonstrate that GCV-PCL-chitosan micelles were non-toxic and biocompatible.
In summary, we have shown that antiviral GCV can be used as the sole initiator in ring-opening
polymerization of ε-CL, forming hydrophobic GCV-PCL. GCV-PCL can be further conjugated with
chitosan for the formation of polymeric micelles. Polymeric micelles tagged with GCV have the drug
attached to the polymer rather than housed in the core. Our results show that GCV-tagged polymeric
micelles are biocompatible and have a small size for therapeutic use.
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Figure 6. Viability and morphology of HT29 colorectal cancer cells challenged with
GCV-PCL-chitosan polymeric micelles at different dosages ranging from 0–1 mg/mL.
(A) Viability of HT29 cells after 48 h treatment determined by MTT assay; (B) untreated cells,
0 h; (C) micelle treated cells, 0 h; (D) untreated cells, 48 h; (E) micelle treated cells, 48 h.
3. Experimental Section
3.1. Materials
GCV was purchased from Biotang Inc. (Lexington, MA, USA). N,N'-dicyclohexylcarbodiimide
(DCC), ε-CL, pyrene, and succinic anhydride were purchased from Acros Organics (Geel, Belgium).
Sn(Oct)2, CDCl3 with 1% tetramethylsilane (TMS), deuterated dimethyl sulfoxide (DMSO-d6), dimethyl
sulfoxide (DMSO), tetrahydrofuran (THF), dichloromethane (DCM), methanol, 2-propanol, hexane,
toluene, and chitosan oligosaccharide lactate (MW = 5000) were all purchased from Sigma-Aldrich
(St. Louis, MO, USA). Ethyl ether was purchased from J.T. Baker (Austin, TX, USA).
N-Hydroxysuccinimide (NHS) was purchased from Alfa Aesar (Ward Hill, MA, USA). Acetone was
purchased from Pharmco-AAPER (Shelbyville, KY, USA). Pyridine and hydrochloric acid (HCl) were
purchased from EMD (Philadelphia, PA, USA). Sodium chloride (NaCl) and magnesium sulfate were
purchased from Showa (Tokyo, Japan). All reagents were used as received without further purification.
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3.2. Characterization Methods
Gel permeation chromatography (GPC) analyses were performed on a Waters 1525 binary HPLC
pump equipped with a Waters 2414 refractive index detector (Milford, MA, USA). Waters styragel HR
3 (MW = 500–30,000) and HR 4E (MW = 50–100,000) columns were equipped. Molecular weight
calibration was performed with polystyrene standards that covered a MW range of 400–4.3 × 104. GPC
analyses were performed in THF at a flow rate of 1 mL·min−1 with an injected volume of 50 µL.
1
H-NMR spectra were obtained from a Varian Unity/Inova 400 MHz instrument (Sparta, NJ, USA).
3.3. Synthesis of GCV-Tagged Amphiphilic Polymers
GCV (50 mg) was weighed and mixed with ε-CL (2.25 mL) under a sonication bath for 5 min at
room temperature. Sn(Oct)2 (0.5 wt % of ε-CL) was then added into the mixture. The entire solution
was placed into a 3-necked round-bottom flask. The system was purged with nitrogen and immersed in
an oil bath at 140 °C for 24 h. The crude product was cooled to room temperature, dissolved in DCM,
and precipitated by cold methanol. The product was then vacuum dried by a rotary evaporator at 40 °C.
GCV-PCL (0.5 mmol) and succinic anhydride (1 mmol) were weighed and dissolved in toluene in a
3-necked round-bottom flask. One mmol pyridine was added and the solution was reacted under
nitrogen at 70 °C for 48 h. The product was then precipitated by cold hexane, and spun down. The
pellet was re-dissolved in DCM and washed twice each with 10% (v/v) HCl and saturated NaCl
solution. The organic phase was isolated and dried with magnesium sulfate then filtered. The
carboxylated GCV-PCL was recovered by precipitation in cold hexane and then vacuum dried by
rotary evaporation at 40 °C.
GCV-PCL-COOH (0.54 mmol) and NHS (2.7 mmol) were weighed and mixed in 15 mL DCM, and
then DCC (2.7 mmol) was added. The reaction was run under a nitrogen environment at room
temperature for 24 h. The precipitated byproduct 1,3-dicyclohexylurea was removed by vacuum
filtration. The filtrate was added into 35 mL diethyl ether and cooled to 4 °C for 4 h to precipitate
GCV-PCL-NHS. The precipitate was collected by centrifugation at 3500 rpm for 5 min, washed with
2-propanol and solvent removed by rotary evaporation at 40 °C.
GCV-PCL-NHS (10 mg) was dissolved in 5 mL acetone and slowly added to chitosan solution
(20 mg chitosan oligosaccharide lactate dissolved in 25 mL deionized water). The mixture, purged
with nitrogen, was stirred in a round-bottom flask for 24 h. The reacted solution was vacuum dried to
remove acetone and then lyophilized. The amphiphilic polymer was then dissolved in DCM and
dialyzed (MWCO = 6–8 kD, Spectra/Por) against pure DCM to remove unreacted chitosan.
GCV-PCL-chitosan was recovered by rotary evaporation at 40 °C.
3.4. Preparation of Polymeric Prodrug Micelles
10 mg of GCV-PCL-chitosan was dissolved in 2 mL acetone. The solution was then added
dropwise to 10 mL deionized water under sonication. Acetone was removed by rotary evaporation and
the final solution was collected by filtering through a 0.45 µm filter.
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3.5. Size and Charge of Polymeric Prodrug Micelles
The average particle size of polymeric prodrug micelles was determined by a dynamic light
scattering (DLS) instrument (Zetasizer Nano ZS, Malvern Instruments, Westborough, MA, USA)
equipped with a red laser at a wavelength of 633 nm and scattering angle of 90° at 25 °C. The zeta
potential of the micelles dispersed in deionized water was determined with a zeta potential analyzer
(Zetasizer Nano ZS).
3.6. Drug Release Kinetics
Polymeric prodrug micelles at a concentration of 1 mg·mL−1 were made in phosphate buffered
saline (PBS) (1 M, pH 7.4) at 25 °C. Two mL of solution was placed in a dialysis tube (Float-A-Lyzer,
Spectrum Labs, Rancho Dominguez, CA, USA) with a MWCO of 3.5–5 kD. The dialysis bag was then
immersed in 50 mL PBS at 37 °C. At specified time intervals, 5 µL of sample was removed and
replaced with fresh PBS. The amount of GCV released was analyzed by a plate reader (BioTek,
Winooski, VT, USA) at 254 nm. All experiments were carried out in triplicate.
3.7. Cytotoxicity Test
24-well plates were seeded with human colorectal HT29 cells (HTB-38; ATCC, Manassas, VA,
USA) suspended in 0.5 mL Dulbecco’s modified Eagles’ medium (DMEM, Corning Cellgro,
Manassas, VA, USA) supplemented with 10% fetal bovine serum (FBS, Atlanta Biologicals, Flowery
Branch, GA, USA) and 1% penicillin-streptomycin (Sigma) and incubated at 37 °C in 5% CO2
balanced with humidified air for 24 h. In each well, 500 µL of 2 mg·mL−1 GCV-PCL-chitosan
polymeric micelles (filtered by a 0.45 µm filter) was added. After incubation for 48 h, cell viability
was assessed using MTT assay. 200 µL of sterile MTT solution in PBS (4 mg·mL−1) was added into
the culture wells and incubated for 4 h. The medium containing unreacted MTT was removed and
300 µL DMSO was added to dissolve the insoluble purple formazan crystals formed in cellular
mitochondria. The absorbance at 590 nm was measured with a plate reader (BioTek) and results were
recorded as viability percentage calculated against the control group without micellar challenge. All
experiments were carried out in triplicate.
4. Conclusions
In conclusion, GCV-PCL-chitosan polymeric micelles were synthesized and characterized. Our
results show that ring-opening polymerization of ε-CL can be initiated by guanosine-based prodrug
GCV with Sn(Oct)2 as the catalyst. GCV-PCL can be easily produced compared to conventional
methods, eliminating drug-loading steps, enhancing drug-carrying capacity, and decreasing production
cost. Moreover, hydrophilic and cationic chitosan was grafted onto hydrophobic GCV-PCL for the
formation of amphiphilic polymer micelles. 1H-NMR and GPC analysis confirmed the graft of
chitosan to GCV-PCL. Size and zetasizer analysis showed that micelles in the range of 100 nm can be
produced with a positive charge. Additionally, HT29 cells were challenged with GCV-PCL-chitosan
polymeric micelles and showed no toxicity or inhibition of cell proliferation. This study shows that
GCV-PCL-chitosan polymeric micelles are a potential carrier for antiviral drug therapy.
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